NCT03987672

Brief Summary

The study is a self-controlled study in which we will assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula in patients with gastroparesis, relative to their pre-enrollment nutritional diet regimen.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 12, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 17, 2019

Completed
2 months until next milestone

Study Start

First participant enrolled

August 1, 2019

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 18, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 18, 2022

Completed
Last Updated

August 22, 2022

Status Verified

August 1, 2022

Enrollment Period

3 years

First QC Date

June 12, 2019

Last Update Submit

August 18, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change from baseline in Gastroparesis Cardinal Symptom Index (GCSI) Symptoms Index (GCSI) score as measure of the effect of KF Peptide 1.5 nutritional formula.

    9-item measure of severity of gastroparesis symptoms on a scale of 0-5 (none to worst) Higher values represent a worse outcome.

    Screening, Baseline and through end of study (12 weeks)

Secondary Outcomes (4)

  • Change in Patient Assessment of Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM) Disorders-Symptom Severity Index (PAGI-SYM) score as measure of the effect of KF Peptide 1.5 nutritional formula.

    Baseline through end of study (12 weeks)

  • Total energy requirement

    At Baseline and end of study (12 weeks)

  • Inflammatory markers

    Baseline through end of study (12 weeks)

  • Weight

    Baseline through end of study (12 weeks)

Study Arms (1)

Assess Nutritional Effects of Nutritional Formula

OTHER

Self-controlled study in which we will assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula in patients with gastroparesis, relative to their pre-enrollment nutritional formula regimen.

Dietary Supplement: Assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula

Interventions

Kate Farm Peptide 1.5 nutritional Formula

Also known as: Study to Intervene with Nutrition for Gastroparesis
Assess Nutritional Effects of Nutritional Formula

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female gender
  • Ages 18 to 65
  • Established diagnosis of gastroparesis confirmed by gastric emptying study within the last 5 years.
  • No changes to gastroparesis medications in the 3 months prior to recruitment.
  • Patients with hysterectomy, appendectomy, cholecystectomy and fundoplication are ok to participate.
  • Able to give informed consent.
  • Patient willing to supplement diet with Kate Farms
  • Ability to adhere to the study visit schedule and other protocol requirements.

You may not qualify if:

  • Are nursing or pregnant.
  • Diagnosis of mechanical small bowel obstruction within 3 months prior to recruitment
  • Patients with a history of gastric surgery, including gastrectomy, small bowel resection or bariatric surgery
  • The use of narcotic medications in the month prior to study enrollment or during the study period
  • Diagnosis of short gut syndrome
  • Allergic to any ingredients in the Kate Farms formula
  • Untreated small intestinal bacterial overgrowth

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford University School of Medicine

Redwood City, California, 94063, United States

Location

MeSH Terms

Conditions

Gastroparesis

Interventions

Nutritional Status

Condition Hierarchy (Ancestors)

Stomach DiseasesGastrointestinal DiseasesDigestive System DiseasesParalysisNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Nutritional Physiological PhenomenaDiet, Food, and NutritionPhysiological PhenomenaHealth StatusDemographyPopulation Characteristics

Study Officials

  • Linda Anh Nguyen, MD

    Stanford University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Associate Professor

Study Record Dates

First Submitted

June 12, 2019

First Posted

June 17, 2019

Study Start

August 1, 2019

Primary Completion

August 18, 2022

Study Completion

August 18, 2022

Last Updated

August 22, 2022

Record last verified: 2022-08

Data Sharing

IPD Sharing
Will not share

Locations